Recent incidences and differential trends of thyroid cancer in the USA

Mao, Yu; Xing, Mingzhao

doi:10.1530/erc-15-0445

Cited by 183 publications

(132 citation statements)

References 19 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…This variation in actual RAI treatment given is consistent with the regional differences in an opinion on RAI treatment found in the cross-sectional survey by Sawka et al [7]. Variation in management cannot be attributed to variation in the distribution of well-differentiated thyroid cancer across T stage, as found in our study, it was similar between centers and to other studies [8]. …”

Section: Discussionsupporting

confidence: 91%

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010

Rachinsky

Rajaraman

Leslie

et al. 2016

Journal of Thyroid Research

View full text Add to dashboard Cite

Background. Use of radioactive iodine (RAI) ablation has been reported to vary significantly between studies. We explored variation in RAI ablation care patterns between seven thyroid cancer treatment centers in Canada. Methods. The Canadian Collaborative Network for Cancer of the Thyroid (CANNECT) is a collaborative registry to describe and analyze patterns of care for thyroid cancer. We analyzed data from seven participating centers on RAI ablation in patients diagnosed with well-differentiated (papillary and follicular) thyroid cancer between 2000 and 2010. We compared RAI ablation protocols including indications (based on TNM staging), preparation protocols, and administered dose. We excluded patients with known distant metastases at time of RAI ablation. Results. We included 3072 patients. There were no significant differences in TNM stage over time. RAI use increased in earlier years and then declined. The fraction of patients receiving RAI varied significantly between centers, ranging between 20–85% for T1, 44–100% for T2, 58–100% for T3, and 59–100% for T4. There were significant differences in the RAI doses between centers. Finally, there was major variation in the use of thyroid hormone withdrawal or rhTSH for preparation of RAI ablation. Conclusion. Our study identified significant variation in use of RAI for ablation in patients with well-differentiated thyroid cancer both between Canadian centers and over time.

show abstract

Section: Discussionsupporting

confidence: 91%

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010

Rachinsky

Rajaraman

Leslie

et al. 2016

Journal of Thyroid Research

View full text Add to dashboard Cite

show abstract

“…DTC exhibits a lower mortality rate compared with other carcinomas, but certain types of DTC, such as radioiodine refractory differentiated thyroid carcinoma, are difficult to diagnose at an early stage (23,24). Patients with DTC have poor prognosis due to DM (25)(26)(27). Previous studies have indicated that LNM, tumor size, histologic subtype and ETE are risk factors that influence the prognosis of patients with DTC (20,28,29).…”

Section: Discussionmentioning

confidence: 99%

Innovative analysis of distant metastasis in differentiated thyroid cancer

et al. 2020

View full text Add to dashboard Cite

Differentiated thyroid cancer (DTC) is the most common thyroid cancer with a relatively high survival rate. The association between certain risk factors of distant metastasis (DM) remains uncertain. In order to assess the prognosis of patients with DTC better, the present study aimed to investigate the synergistic effects between histologic subtype, tumor size, lymph node metastasis (LNM) status and extrathyroidal extension (ETE) on the incidence of DM in DTC. Data of 96,788 patients with DTC were obtained from the Surveillance, Epidemiology and End Results database. The association between clinicopathological factors and DM was evaluated by univariate and multivariate analyses. The synergistic effects of relevant factors were determined by measuring the relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP) and synergy index (SI). The results demonstrated that tumor size, LNM status, histologic subtype and ETE were independent risk factors for DM [odds ratio (OR)=2.433; P<0.001; OR=3.998; P<0.001; OR=6.266; P<0.001; and OR=3.873; P<0.001, respectively]. In addition, a significant additive synergistic effect on DM was identified between ETE and histologic subtype, ETE and LNM status, as well as between ETE and tumor size (RERI=34.097; AP=0.706; SI=3.585; RERI=6.425; AP=0.410; SI=1.781; and RERI=76.973; AP=0.864; SI=7.930, respectively). Therefore, the results of this study revealed that ETE with follicular thyroid histology, N1 stage or large tumor size may have a synergistic effect on the risk of DM in patients with DTC. These results suggested that individualized treatment may benefit patients with DTC, and when ETE coexists with one of the identified risk factors, radical treatments may be required.

show abstract

“…Thyroid cancer is the most common malignant tumor of the endocrine system and the most common head and neck cancer. The incidence of thyroid cancer has increased significantly in the past two decades [1].…”

Section: Introductionmentioning

confidence: 99%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion:The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

show abstract

Recent incidences and differential trends of thyroid cancer in the USA

Cited by 183 publications

References 19 publications

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010

Innovative analysis of distant metastasis in differentiated thyroid cancer

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Contact Info

Product

Resources

About